Axial Spondyloarthritis (axSpA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Axial spondyloarthritis (axSpA), encompassing both ankylosing spondylitis (AS) and non-radiographic axial SpA, is the most prevalent form of chronic inflammatory arthritis affecting the axial skeleton. AS, impacting 0.1–0.5 percent of the population, manifests with inflammatory back pain, radiographic sacroiliitis, excessive spinal bone formation, and a high incidence of HLA–B27. Conversely, non-radiographic axial SpA, while sharing several similarities with AS, lacks advanced sacroiliac joint damage and spinal ankylosis. Symptoms such as arthralgia, stiffness, and restricted flexibility vary widely across patients and throughout the axial SpA spectrum. Additionally, skeletal manifestations may coexist with conditions like uveitis, psoriasis, and inflammatory bowel disease (IBD), significantly impacting patients’ physical and social well-being and disrupting daily life. Despite the substantial burden posed by axial SpA, including notable pain, stiffness, and compromised physical function, there often exists a considerable delay between symptom onset and diagnosis, especially in cases lacking radiographic evidence. FDA-approved medications for axial SpA include Cimzia (certolizumab pegol), Taltz (ixekizumab), Cosentyx (secukinumab), and Rinvoq (upadacitinib).
• The prevalence of Axial Spondyloarthritis (axSpA) in the USA ranges from 350 to 412 cases per 100,000 population.

Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis (axSpA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Axial Spondyloarthritis (axSpA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Axial Spondyloarthritis (axSpA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Axial Spondyloarthritis (axSpA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033